Kenvue is showing better sales, margin, and EPS momentum, but the stock still looks fairly valued rather than compellingly cheap. Its defensive brands and cash generation support the case, while leverage and execution risk keep the rating at Hold.
Kenvue (KVUE) is a Hold for moderate-risk investors seeking a defensive consumer health franchise with improving operating momentum, but the stock does not yet offer enough growth to justify an aggressive stance. Q3 2026 net sales rose 3.2% year over year, organic sales increased 2.9%, adjusted diluted EPS reached $0.29, and adjusted operating margin expanded to 21.9% from 21.5%. Those figures show a business moving in the right direction after a difficult 2025.
The valuation is reasonable rather than distressed. KVUE trades at 22.5x trailing earnings and 16.3x forward earnings, with a PEG ratio of 1.6, enterprise value to revenue of 2.9x, and a free cash flow yield of 7.2%. Revenue growth is 3.0% year over year and earnings growth is 8.5%, so the forward multiple rests on margin improvement and execution rather than rapid top-line expansion.
The investment case has three supporting pillars: trusted brands such as Tylenol, Zyrtec, Neutrogena, Listerine, BAND-AID, and Rogaine; a $15.1 billion fiscal 2025 revenue base spread across three segments; and free cash flow of $1.7 billion in 2025. The counterweight is a leveraged balance sheet, with $8.5 billion of debt against $1.1 billion of cash, plus execution risk tied to the Kimberly-Clark combination and the continuing transformation of the stand-alone company.
Kenvue is a global consumer health company headquartered in Summit, New Jersey. Incorporated in 2022 and listed on the NYSE in May 2023, the company employs approximately 21,780 people and sells products across more than 165 countries.
The portfolio spans over-the-counter medicine, oral care, skin care, hair care, baby care, wound care, women's health, smoking cessation, vitamins, and personal care. Major brands include Tylenol, Zyrtec, Motrin, Nicorette, Pepcid, Neutrogena, Aveeno, OGX, Rogaine, Listerine, BAND-AID, Johnson's, Stayfree, and o.b.
Kenvue reported $15.1 billion of fiscal 2025 revenue. The business is large enough to command global retailer relationships, but its category breadth also creates complexity. Management identified 115 brands, with 41 brands accounting for more than three-quarters of sales across at least one region. That concentration creates an opportunity to direct marketing and innovation toward the brands with the greatest commercial impact.
Self Care is Kenvue's largest segment, generating $6.4 billion of fiscal 2025 revenue, or 42.2% of the total. It includes pain care, allergy, cough, cold and flu, digestive health, eye care, and smoking cessation. Q3 2026 net sales increased 5.9%, supported by Motrin, Nicorette, Pepcid, and continued U.S. share gains for Tylenol.
Skin Health and Beauty generated $4.1 billion in fiscal 2025 revenue, or 27.2% of the total. Q3 2026 net sales increased 0.1%, while organic sales declined 0.5%. Hair Care was a bright spot, with low double-digit organic growth and a fourth consecutive quarter of market share gains for Rogaine. Neutrogena Cloud Tech sun care and the OGX ProGrowth platforms added innovation to the segment.
Essential Health produced $4.6 billion of fiscal 2025 revenue, or 30.6% of the total. Q3 2026 net sales and organic sales both rose 2.5%, supported by Johnson's Baby, Stayfree, o.b., and BAND-AID. The segment contains several repeat-purchase categories, although Listerine has faced share pressure in the U.S. and needs stronger positioning in alcohol-free mouthwash.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Tylenol remains one of KVUE's most important assets. Management reported 12 consecutive quarters of U.S. share improvement for adult Tylenol in the Q2 2025 discussion, while the brand retained its position as the number-one health care professional recommended brand. Tylenol Precise Nighttime and Children's Tylenol Natural Apple Flavor extend the brand into adjacent needs and respond to demand for dye-free and artificially flavored product alternatives.
Zyrtec delivered another example of brand resilience. Management reported that Zyrtec strengthened its leadership position and increased household penetration across adult and children's franchises despite a weak allergy season. Q3 2026 results also showed Nicorette delivering low double-digit organic sales growth and Pepcid outperforming its category.
Skin and personal care products provide the more visible growth opportunity. Rogaine recorded its fourth consecutive quarter of market share gains, while OGX ProGrowth and ProGrowth + Peptide gained momentum. In the earlier Q2 2025 period, the OGX Bond Protein Repair launch was described as Kenvue's best-performing innovation of the year and secured additional distribution.
Kenvue's competitive advantage rests on brand trust, distribution, scientific positioning, and repeat purchase behavior. These advantages are strongest in OTC medicine and wound care, where consumers place value on familiarity and perceived safety. They are less durable in beauty and personal care, where trends change quickly and private-label products can narrow the price gap.
The Q3 2026 innovation slate included Neutrogena Cloud Tech sun care with BEMT and proprietary technology, expanded Neutrogena Ultra Sheer Sun, OGX ProGrowth products, Stayfree Secure Nights and XpertXL in India, Listerine On-The-Go mouthwash packets, Johnson's Baby innovations in Latin America, and BAND-AID Brand PRO HEAL 5 Day Protect.
Management has also shifted its innovation philosophy toward fewer, larger initiatives. That approach fits the company's brand concentration: 10 leading brands in each region account for more than two-thirds of regional sales, while the 10 largest markets account for more than three-quarters of sales. Better execution on those platforms has more economic value than a broad launch calendar that spreads resources thinly.
Kenvue is still absorbing the operational consequences of its separation from Johnson & Johnson. Management has been replacing legacy infrastructure, exiting transition service arrangements, modernizing systems, and building stand-alone capabilities in technology, data, planning, and procurement.
The main operational issue is complexity. Management said a long tail of SKUs represents a significant share of total items but only about 1% of sales. Reducing that tail, improving consumption-driven demand forecasting, and concentrating production and marketing on higher-volume platforms can improve inventory efficiency and reduce organizational friction.
Supply chain productivity is already visible in the financial results. Q3 2026 gross margin increased to 59.5% from 59.1%, while adjusted gross margin increased to 61.5% from 61.2%. Management also cited Our Vue Forward and the 2026 Restructuring Initiative as contributors to cost optimization. The main risk is that restructuring savings arrive slower than brand investment, inflation, tariffs, or service-level requirements.
Kenvue operates inside a large consumer health market that the company sizes at approximately $369 billion. Broader personal care market estimates place the global category at roughly $560 billion to $640 billion in 2026, with mid-single-digit annual growth. KVUE's $15.1 billion fiscal 2025 revenue base therefore gives it scale without making the addressable market appear exhausted.
Demand is splitting between products with clear functional benefits and products that face direct price comparison. Science-backed skin care, dermocosmetics, personalized routines, and multifunctional products fit the first group. Basic oral care, baby care, and some OTC categories face stronger private-label pressure. Kenvue's trusted brands provide an advantage when consumers prioritize efficacy, but promotional intensity rises when differentiation is weak.
Digital discovery and e-commerce are becoming more important in personal care. Kenvue's investments in precision marketing, data, AI, and online retail execution fit that shift. The company also benefits from category diversity: Self Care and Essential Health provide defensive demand, while Skin Health and Beauty offers more exposure to premiumization and innovation.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Kenvue sells through retailers, pharmacies, e-commerce platforms, health care professionals, and other consumer channels. The 2025 10-K identified $6.5 billion of U.S. sales within $15.1 billion of total fiscal revenue, showing the importance of the U.S. while confirming that international markets represent a substantial part of the business.
The customer relationship is shaped by availability, shelf placement, digital search ranking, price, and trust. In Q2 2025, management said retailer inventory fluctuations and shipment timing affected reported sales even when consumption grew. That distinction matters because sell-in volatility can make quarterly revenue weaker than underlying household demand.
Kenvue's strongest customer proposition is a combination of recognizable brands and health-related credibility. Tylenol, Zyrtec, Listerine, BAND-AID, and Johnson's benefit from habitual use and broad distribution. The weaker customer position is in categories where shoppers can switch quickly to a retailer brand or a specialist digital-native product.
Kenvue competes with Haleon, Procter & Gamble, Reckitt, Bayer Consumer Health, Sanofi Consumer Healthcare, Beiersdorf, L'Oréal, Unilever, Estée Lauder, Colgate-Palmolive, Church & Dwight, Kimberly-Clark, regional brands, generic manufacturers, and private-label products.
The company has a credible position in Self Care through Tylenol, Zyrtec, Nicorette, Motrin, and Pepcid. Its Essential Health portfolio has strong names in wound care, baby care, oral care, and women's health. Skin Health and Beauty is more contested, with large global competitors and faster product cycles placing greater pressure on marketing returns and innovation quality.
Kenvue's $15.1 billion revenue base provides meaningful scale, but the company does not have the same breadth as the largest diversified consumer product groups. Its moat is therefore practical rather than structural: trusted brands, health care professional recommendations, retailer relationships, global distribution, and scientific know-how. The 7.2% free cash flow yield gives Kenvue room to fund brand support, debt service, and operating improvements, but debt limits strategic flexibility.
Consumer value sensitivity is the main macro pressure. Industry research describes a split between premium products with visible benefits and trade-down behavior in less differentiated categories. That pattern fits Kenvue's portfolio: Rogaine, Neutrogena, and science-backed skin care can support premium positioning, while basic oral care and some personal care products face direct value comparisons.
Tariffs are a specific cost risk. Management estimated a gross annualized tariff impact of approximately $150 million, with a smaller effect in 2025 because of timing. Currency is another variable across Kenvue's global footprint. Q3 2026 sales included a 0.3% foreign currency benefit, while Q2 2025 adjusted EPS absorbed an approximately $0.01 currency headwind.
The proposed combination with Kimberly-Clark adds transaction and integration considerations to the macro backdrop. Kenvue's Q3 2026 materials stated that the company was nearing completion of the combination and did not provide forward-looking guidance because of the transaction. That event can influence capital allocation, operating priorities, and the valuation investors assign to the stand-alone business.
$8.5 billion of debt versus $1.1 billion of cash leaves Kenvue with a leveraged balance sheet that limits flexibility even as free cash flow reached $1.7 billion in 2025.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 2026 net sales rose 3.2% and adjusted operating margin expanded to 21.9%, showing that Kenvue's earnings recovery is gaining traction.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue growth of 3.0% and earnings growth of 8.5% suggest Kenvue's outlook depends more on margin improvement than on rapid top-line acceleration.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 22.5x trailing earnings, 16.3x forward earnings, and a 7.2% free cash flow yield, Kenvue screens as reasonable rather than deeply discounted.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report's valuation framework points to $19.50 as fair value, with upside requiring stronger execution and a cleaner balance-sheet story.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Kenvue is a credible consumer health franchise in the middle of an operational reset. Q3 2026 delivered the strongest evidence so far that the reset is gaining traction: sales grew 3.2%, organic sales increased 2.9%, adjusted operating margin expanded, and Self Care and Essential Health posted solid segment growth.
The business still needs to prove that improvement can persist across more than a few quarters. Fiscal 2025 revenue declined from 2024, the current ratio is 0.96, debt is $8.5 billion, and Skin Health and Beauty remains near flat on organic sales. Those facts keep the recommendation at Hold rather than Buy.
For a medium-term investor, the most durable part of the thesis is the combination of trusted brands, recurring consumer demand, and $1.7 billion of annual free cash flow. The strongest upside path runs through sustained share gains, disciplined innovation, supply chain productivity, and debt management. Until those gains produce a higher growth rate, KVUE is better treated as a stable holding than a market-leading opportunity.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Kenvue Inc. (KVUE) slipped after a narrow EPS miss offset a revenue beat, but the deeper story is more nuanced. Self Care drove growth, Skin Health lagged, margins improved, and free cash flow strengthened, even as the company withheld guidance amid its Kimberly-Clark transaction.
Kenvue Inc. (KVUE) slips 0.6% after reporting earnings misses, pressuring the stock as investors react to weaker-than-expected results.
Kenvue Inc. (KVUE) slips after an earnings miss, but the real story is in the deeper analysis. This breakdown examines what drove the results, how management’s outlook compares with expectations, and what the numbers may signal for the stock ahead.